Research Areas

A Phase II, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study of the Efficacy, Safety and Tolerability of TAK-491 in Subjects with Mild to Moderate Uncomplicated Essential Hypertension

A Randomized, Double-Blind, Parallel Group Evaluation of an Investigational Medication 0.8 mg Compared to an Investigational Medication 0.4 mg and Placebo/Pravastatin 20 mg Once Daily in Patients with Hypercholesterolemia

A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of An Investigational Medication in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia

A Phase 3, Open-Label, Multi-Center, Randomized, Parallel Group Study of The Efficacy and Safety of Fixed Combination Investigational Medication/Atorvastatin Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Week In Subjects with Dyslipidemia

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Does-Ranging Study to Assess the Efficacy, Safety, and Tolerability of An Investigational Medication in Patients with Primary Hypercholesterolemia or Mixed Hyperlipidemia

A Multicenter, Randomized, Double-Blinded, Prospective Study Comparing the Safety and Efficacy of An Investigational Combination Therapy to Fenofibric Acid and Atorvastatin Calcium Monotherapy in subjects with Mixed Dyslipidemia

A Multicenter, Randomized, Double-Blinded, Prospective Study Comparing the Safety and Efficacy of An Investigational Combination Therapy to Fenofibric Acid and Simvastatin Monotherapy in subjects with Mixed Dyslipidemia

A Multicenter, Randomized, Double-Blind, Eight Week Comparative Efficacy and Safety Study of an Investigational Medication 20 mg, an Investigational Medication 40 mg and Omeprazole 20 mg in Study Subjects with Erosive Esophagitis

A Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Efficacy of an Investigational Medication for Four Weeks in Out-Patients with Chronic Obstructive Pulmonary Disease

A Double-Blind Flexible Dose Study of a Transdermal Investigative Medication in the Treatment of Children with Attention-Deficit Hyperactivity Disorder

A 4-Year, Double-Blind, Randomized, Placebo-Controlled Study of an Investigational Medication as Secondary Prevention of CHD in Patients with (Type II) Non-Insulin-Dependent Diabetes Mellitus

A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Investigate the Efficacy, Tolerability, and Safety of an Investigational Medication in the Treatment of Patients with Non-Insulin Dependent Diabetes Mellitus (Type II) Inadequately Controlled with Diet and Metformin

An Investigational Medication in Type II Diabetes: A Placebo Controlled, Double-Blind, Randomized Six Month Fixed Dose Safety Study

A Multicenter, Double-Blind, Randomized, Combination Study to Prospectively Evaluate the Safety and Efficacy of Two Oral Fixed Doses of an Investigational Medication Plus Glyburide Compared to Placebo Plus Glyburide in Subjects with Non-Insulin-Dependent Diabetes Mellitus on Sulfonylureas

A Randomized Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Trial of Investigational Medication in Type II Diabetes Mellitus Patients

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 26-Week Dose-Response Study of An Investigational Medication with Active Comparator in Subjects with Type 2 Diabetes

A 26-Week, Multicenter, Open-label, Parallel, 2:1 Randomized Treat-to-Target Trial Comparing Efficacy and Safety of an investigational medication Versus Insulin Glargine using a Basal-Bolus Regimen with Insulin Aspart as Mealtime Insulin in Subjects with Type 2 Diabetes

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of An Investigational Medication to Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control on Glimepiride Alone or in Combination with Metformin

A Study to Assess the Efficacy and Tolerability of An Investigational Medication Co-Administered with Insulin in Patients with Type 2 Diabetes

A Phase 3B Randomized, Open-Label, Comparator Controlled, Multicenter Study to Evaluate the Metabolic Effect of A Marketed Drug, Rosiglitazone, and A Marketed Drug Plus Rosiglitazone in Subjects with Type 2 Diabetes Mellitus Treated with Metformin